Company · CIK 0001422143 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Kura Oncology, Inc. · KURA
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 SForm 4 → | Sep 25, 4:05 pm EDT | Francis BurrowsChief Scientific Officer | 20,726 | $10.83 | $224,514 | 42,327 | −32.9% | |
| Sep 24, 2026 MForm 4 → | Sep 25, 4:05 pm EDT | Francis BurrowsChief Scientific Officer | 30,000 | $6.15 | $184,500 | 63,053 | — | |
| Aug 24, 2026 PForm 4 → | Aug 24, 5:30 pm EDT | Troy Edward WilsonPresident and CEO, Director | 100,000 | $12.39 | $1,239,000 | 479,194 | +26.4% | |
| Aug 21, 2026 SForm 4 → | Aug 24, 5:30 pm EDT | Brian T. PowlChief Commercial Officer | 4,345 | $11.89 | $51,663 | 169,269 | −2.50% | 10b5-1 |
| Aug 19, 2026 SForm 4 → | Aug 21, 4:30 pm EDT | Teresa Brophy BairChief Legal Officer | 31,487 | $12.63 | $397,681 | 195,444 | −13.9% | 10b5-1 |
| Aug 17, 2026 PForm 4 → | Aug 17, 4:45 pm EDT | Troy Edward WilsonPresident and CEO, Director | 100,000 | $11.12 | $1,112,000 | 379,194 | +35.8% |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 MForm 4 → | Sep 25, 4:05 pm EDT | Francis BurrowsChief Scientific Officer | 30,000 | — | — | 0 | — | |
| Sep 8, 2026 AForm 4 → | Sep 10, 4:30 pm EDT | Jennifer FulkChief Financial Officer | 450,000 | — | — | 450,000 | — | 10b5-1 |